Search for a trial

A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer

This study has been transitioned to CTIS with ID 2023-503797-21-00 check the CTIS register for the current data. The purpose of this study is to determine if the combination of relatlimab and nivolumab improves overall survival (OS) in all…